Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
BUSINESS
Krystal Biotech Snags Japan Nod for Vyjuvek as 1st Topical Gene Therapy
Krystal Biotech said on July 25 that it has won Japanese regulatory approval for Vyjuvek Gel (beremagene geperpavec), the country’s first-ever gene therapy administered via topical application. The treatment is indicated for dystrophic epidermolysis bullosa (DEB), with the Japanese approval…
To read the full story
Related Article
- Krystal Launches Japan’s First DEB Therapy Vyjuvek Gel
October 22, 2025
- Listing OK’ed for Krystal’s Vyjuvek Gel, Japan’s First Topical Gene Therapy
October 16, 2025
- Japan to Apply Drug Pricing Rules for Krystal Gene Therapy: Chuikyo
August 28, 2025
- Vyjuvek Gel, 1st Topical Gene Therapy, Poised for Approval in Japan
July 8, 2025
BUSINESS
- AG Price Parity Plan Stokes Industry Fears of Patient, Pharmacy Defections
December 12, 2025
- Kyowa Kirin Names Abdul Mullick as Next CEO from March 2026
December 12, 2025
- Regeneron Files Libtayo for Squamous Cell Carcinoma in Japan
December 12, 2025
- Chugai to Donate 100 Million Yen to Support Nobel Laureate Sakaguchi’s Research
December 12, 2025
- Regeneron Lines Up 5 Late-Stage Assets for Japan: Commercial Head
December 11, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…